Navigation Links
Isis Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference

CARLSBAD, Calif., Jan. 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 4:30 p.m. PT in San Francisco, CA.


A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website,  A replay will be available on the Isis website within 48 hours and will be archived for a limited time.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 31 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at

This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.  In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals to Present at Biotech Showcase 2014 Investor Conference
2. Global Radiopharmaceuticals Market Report 2013 - 2018
3. Pre-Market Update: MGT Capital Investments, National American University Holdings and Actinium Pharmaceuticals
4. ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals
5. New Appointments, and Share Price Movements - Research Report on Humana, Illumina, Edwards Lifesciences, Aegerion Pharmaceuticals, and CytRx
6. Taiwan Spends a High Percentage of its Healthcare Budget on Pharmaceuticals, but Second Generation Healthcare Reform is Transforming the Market Landscape
7. Valeant Pharmaceuticals To Present At Industry Conferences
8. Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
9. Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
10. Jazz Pharmaceuticals And Gentium S.p.A. Announce Agreement For Jazz Pharmaceuticals To Acquire Gentium For $57.00 Per Share
11. Educational Grant Awarded to Winner of Ferring Pharmaceuticals Inaugural Heart to Heart Video Contest
Post Your Comments:
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Un nuevo enfoque combina la inmunoterapia con la terapia ... Clinical Cancer Research . --> ...
(Date:11/26/2015)... -- --> --> Juntendo ... optimal contrast weighting of MRI for patients with Multiple ... research agreement with SyntheticMR in order to use SyMRI in ... possible to generate multiple contrast images from a single scan ... thus making it possible to both fine tune images and ...
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the French Drugs ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated corporate housing service ... 2015, featured apartment community: Epic. In showcasing this featured apartment community in San Jose, ... Area rental market to efficiently find housing suitable to their needs by showcasing quality ...
(Date:11/28/2015)... ... 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, ... possible savings of up to 20% off orders $80 or more to free gifts with ... few hours. , As a competitive e-commerce website for skin care and cosmetic needs, customers ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... carried out by the University of Toronto and the University of British Columbia suggested ... hospitalizations for head injuries. The article explains that part of the reason for the ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... and convenient way to dispense prescription medications at home, so he invented the ... to monitor and dispense prescription medications. In doing so, it could help to ...
(Date:11/27/2015)... ... 27, 2015 , ... ProSidebar: Fashion is a set of 30 ... ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX production. ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease of ...
Breaking Medicine News(10 mins):